Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA grants priority review to AstraZeneca, Merck & Co.'s filing for Lynparza in first-line maintenance setting for ovarian cancer

firstwordpharmaNovember 13, 2018

Tag: Lynparza , ovarian cancer , FDA , Lynparza

PharmaSources Customer Service